# Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

> **NCT05796089** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Trans Tasman Radiation Oncology Group** · enrollment: 35 (estimated)

## Conditions studied

- Extensive-Stage Small-Cell Lung Cancer

## Interventions

- **RADIATION:** Thoracic Radiotherapy
- **DRUG:** Etoposide with Carboplatin or Cisplatin
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05796089
- **Lead sponsor:** Trans Tasman Radiation Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-02-28
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05796089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05796089, "Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05796089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*